242
Highlights include:
3 Market capitalization $78.5 million approx.
3 4% debt-to-equity (June 30 2017) – low risk
3 Cash on hand $14.2 million (June 30 2017) to support growth initiatives with additional $17.5 bought deal financing (and can increase to $20.125 million if Over-Allotment Option is exercised in full)
3 Low number of options outstanding (8 million @ $0.75 exercise price)
3 Warrants exercisable at $1.00 (18.67 million, inclusive of 2.0 million brokers’ warrants) – compared with current share price of $0.92
3 Approximately 70% shareholders are insiders
3 Estimated EV/EBITDA at 4.3x in 2018 and EV/Rev of 0.8x (industry average of around 38.5x and 7.1x respectively)
3 United Greeneries sales license received October 2017
3 32 different unique strains
3 Fully funded capacity expansion
3 Phase 2 clinical trials conducted in Israel on Satipharm’s Gelpell Microgel CBD capsules in treating intractable epilepsy in children, and spasticity and pain in Multiple Sclerosis – key data in development of capsules as perscription drug for the condition
3 First-mover in Australia – exported capsules earlier this year and have started selling in October (one of the 1st available to legal cannabis users in the country)
3 No U.S. operations or assets – complies with TMX Money Group listing requirements
Truly becoming a company with global aspirations and so far the track record speaks for themselves. Fully funded expansion plans that will increase their capacity significantly, recently granted sales license with wholesale agreements in place already, $14.2 million in cash on hand, and another $17.5-20.125 million coming, HVST is diversified and well-positioned for the existing medical and proposed legal recreational market. Expansion plans are on schedule to meet the surge in demand anticipated. Its relatively low market cap and shares outstanding, owning a late stage ACMPR applicant and exports to Australia and Europe are just a few reasons why HVST is a case study in this months issue of CannaInvestor Magazine Canada.